FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1996003546> ?p ?o ?g. }

• W1996003546 endingPage "277" @default.
• W1996003546 startingPage "267" @default.
• W1996003546 abstract "Summary The theory that Fas ligand (FasL)‐expressing tumours are immune‐privileged and can directly counterattack Fas‐expressing effector T lymphocytes has recently been questioned and several alternative mechanisms have been proposed. To address this controversial issue, we analysed the impact of FasL‐expressing tumours on in vivo ‐primed cytotoxic T lymphocytes (CTLs) and the mechanisms involved. CTLs were obtained from the peritoneal cavity (PEL) after in vivo priming with syngeneic or allogeneic murine tumour cells. We have found that PEL populations undergo Fas‐based apoptotic cell death when co‐cultured with FasL‐expressing tumour cells and that PEL destruction of cognate targets in a 51 Cr‐release assay was markedly inhibited by the pre‐exposure to either cognate or non‐cognate tumour cells expressing FasL. Furthermore, cytocidal function of PEL was markedly inhibited by preincubation with FasL‐negative tumour cells, if and only if they were the cognate targets of the CTL; this CTL inhibition involved FasL–Fas interactions. The killing function of ‘bystander’ PELs, reactive to a third‐party target cell, was inhibited by co‐cultivation with PELs mixed with their cognate target. This activation‐induced CTL fratricide was not influenced by the expression of FasL on the cognate target cells. These studies demonstrate the existence of two distinct pathways whereby FasL‐expressing cells inhibit in vivo ‐primed FasL‐ and Fas‐expressing CTLs: first, by FasL‐based direct tumour counterattack, and second, by FasL‐mediated activation‐induced cell death of the CTLs, which is consistent with the concept that FasL expression in vivo could play a role in inducing immune privilege." @default.
• W1996003546 created "2016-06-24" @default.
• W1996003546 creator A5001441814 @default.
• W1996003546 creator A5008655303 @default.
• W1996003546 creator A5011569932 @default.
• W1996003546 creator A5063663265 @default.
• W1996003546 date "2002-03-01" @default.
• W1996003546 modified "2023-10-18" @default.
• W1996003546 title "Immune privilege and FasL: two ways to inactivate effector cytotoxic T lymphocytes by FasL-expressing cells" @default.
• W1996003546 cites W1482540117 @default.
• W1996003546 cites W1489777708 @default.
• W1996003546 cites W1518444064 @default.
• W1996003546 cites W1527997848 @default.
• W1996003546 cites W1595168222 @default.
• W1996003546 cites W1598929083 @default.
• W1996003546 cites W1750539994 @default.
• W1996003546 cites W1945522850 @default.
• W1996003546 cites W1973792489 @default.
• W1996003546 cites W1976692354 @default.
• W1996003546 cites W1977876194 @default.
• W1996003546 cites W1978018492 @default.
• W1996003546 cites W1989600187 @default.
• W1996003546 cites W1992386229 @default.
• W1996003546 cites W1992716221 @default.
• W1996003546 cites W1994504877 @default.
• W1996003546 cites W1996174406 @default.
• W1996003546 cites W2002503549 @default.
• W1996003546 cites W2005770035 @default.
• W1996003546 cites W2016198585 @default.
• W1996003546 cites W2036952779 @default.
• W1996003546 cites W2041466047 @default.
• W1996003546 cites W2045068005 @default.
• W1996003546 cites W2045796964 @default.
• W1996003546 cites W2049525996 @default.
• W1996003546 cites W2065413461 @default.
• W1996003546 cites W2066598150 @default.
• W1996003546 cites W2071055800 @default.
• W1996003546 cites W2076229621 @default.
• W1996003546 cites W2096950793 @default.
• W1996003546 cites W2098593116 @default.
• W1996003546 cites W2135400695 @default.
• W1996003546 cites W2146985533 @default.
• W1996003546 cites W2149944442 @default.
• W1996003546 cites W2168747001 @default.
• W1996003546 cites W2168945225 @default.
• W1996003546 doi "https://doi.org/10.1046/j.1365-2567.2002.01380.x" @default.
• W1996003546 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1782670" @default.
• W1996003546 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11918688" @default.
• W1996003546 hasPublicationYear "2002" @default.
• W1996003546 type Work @default.
• W1996003546 sameAs 1996003546 @default.
• W1996003546 citedByCount "38" @default.
• W1996003546 countsByYear W19960035462012 @default.
• W1996003546 countsByYear W19960035462013 @default.
• W1996003546 countsByYear W19960035462014 @default.
• W1996003546 countsByYear W19960035462015 @default.
• W1996003546 countsByYear W19960035462019 @default.
• W1996003546 countsByYear W19960035462020 @default.
• W1996003546 countsByYear W19960035462021 @default.
• W1996003546 crossrefType "journal-article" @default.
• W1996003546 hasAuthorship W1996003546A5001441814 @default.
• W1996003546 hasAuthorship W1996003546A5008655303 @default.
• W1996003546 hasAuthorship W1996003546A5011569932 @default.
• W1996003546 hasAuthorship W1996003546A5063663265 @default.
• W1996003546 hasBestOaLocation W19960035461 @default.
• W1996003546 hasConcept C147969180 @default.
• W1996003546 hasConcept C150903083 @default.
• W1996003546 hasConcept C153911025 @default.
• W1996003546 hasConcept C154317977 @default.
• W1996003546 hasConcept C167672396 @default.
• W1996003546 hasConcept C190283241 @default.
• W1996003546 hasConcept C19106626 @default.
• W1996003546 hasConcept C202751555 @default.
• W1996003546 hasConcept C203014093 @default.
• W1996003546 hasConcept C207001950 @default.
• W1996003546 hasConcept C2781185574 @default.
• W1996003546 hasConcept C31573885 @default.
• W1996003546 hasConcept C502942594 @default.
• W1996003546 hasConcept C55493867 @default.
• W1996003546 hasConcept C66008609 @default.
• W1996003546 hasConcept C86803240 @default.
• W1996003546 hasConcept C8891405 @default.
• W1996003546 hasConcept C95444343 @default.
• W1996003546 hasConceptScore W1996003546C147969180 @default.
• W1996003546 hasConceptScore W1996003546C150903083 @default.
• W1996003546 hasConceptScore W1996003546C153911025 @default.
• W1996003546 hasConceptScore W1996003546C154317977 @default.
• W1996003546 hasConceptScore W1996003546C167672396 @default.
• W1996003546 hasConceptScore W1996003546C190283241 @default.
• W1996003546 hasConceptScore W1996003546C19106626 @default.
• W1996003546 hasConceptScore W1996003546C202751555 @default.
• W1996003546 hasConceptScore W1996003546C203014093 @default.
• W1996003546 hasConceptScore W1996003546C207001950 @default.
• W1996003546 hasConceptScore W1996003546C2781185574 @default.
• W1996003546 hasConceptScore W1996003546C31573885 @default.
• W1996003546 hasConceptScore W1996003546C502942594 @default.
• W1996003546 hasConceptScore W1996003546C55493867 @default.
• W1996003546 hasConceptScore W1996003546C66008609 @default.

• next